A bright and promising new path is opening for the country’s pharmaceutical industry after the pandemic. Along with that future is Hau Giang Pharmaceutical, one of the leading pharmaceutical enterprises in Vietnam.
In the period 2020-2021, due to the impact of the Covid-19 pandemic, Vietnam’s pharmaceutical industry has faced many difficulties due to supply chain disruptions, high prices of input materials, and transportation. Along with that, the anti-epidemic measures also made the market somewhat stagnant.
However, the market gradually improved when entering 2022, when the epidemic gradually passed. According to research by KIS Securities Joint Stock Company, collected from 29 listed companies in the industry, in the first quarter of the year, although industry revenue decreased, net profit still increased positively by 25.4% compared to the same period last year. term 2021.
Entering the second quarter of 2022, the recovery of the industry is still maintained at a slow pace, but there are businesses ready to return to the race track. The bright spot that significantly contributes to the driving force for the market is DHG Pharma. As of the first half of the year, the company achieved 2,184 billion dongs in revenue and 490 billion dongs in profit after tax, up more than 11% and 21% respectively over the same period last year.
Not only recovering this year but the pharmaceutical industry is also forecasted to maintain its growth momentum in the coming years. According to a forecast by Fitch Solutions, the revenue of Vietnam’s pharmaceutical industry this year may reach VND 155.8 trillion, up 9.03% compared to 2021. By 2026, revenue may reach more than VND 216 trillion, with an increase. maintained at over 8% annually.
Every year, DHG Pharma implements many programs and activities for the community.
“Driven by a large population and efforts to implement universal health care, Vietnam’s healthcare market will experience strong growth in the coming years,” said Fitch Solutions. This unit forecasts spending on health care in Vietnam this year may reach 22.4 billion USD. By 2031, this figure could reach $37.7 billion, with an annual growth of around 7.8%.
Accompanying the development of the industry and the spending needs of people’s health and health care, DHG Pharma has quickly accelerated, making constant efforts from production to product distribution as soon as it is extended. way to be removed. Many important milestones were established in turn this year.
Not stopping at 2 pharmaceutical production lines meeting JAPAN GMP standards, in July 2022, DHG Pharma started construction of a new betalactam factory with international GMP standards, expected to come into operation in 2024, helping double the current capacity.
In the distribution segment, not only continue to promote strategic and key drug products such as Hapacol, Klamentin, Medlon, Bocalex… DHG Pharma has also recently distributed high-quality health care products such as water collagen ALFE from Japan…
DHG Pharma has also recently distributed high-quality health care products such as ALFE Water Collagen from Japan…
With its prestige and contributions, the company has continuously received awards and titles such as “Top 50 best-listed companies” (Forbes Vietnam) for 10 consecutive years, and “Top 50 trading companies in Vietnam”. most effective in Vietnam” (Nip Cau Investment Newspaper) from 2011-2020, for 6 consecutive years ranked “Top 10 most prestigious pharmaceutical companies in Vietnam” by Vietnamreport.
With a promising market, improved capacity, and the mind and vision of a leading enterprise, DHG Pharma has a solid tripod to enter a new phase of the post-Covid-19 pharmaceutical industry. There, the prestige, quality and inclusiveness of domestic enterprises will improve day by day, gradually making their mark on the domestic and international markets.